Synonyms
CTLA4Ig; CTLA-4-Ig
Definition
CD80/CD86 inhibitors are protein constructs which bind and inactivate CD80/CD86 on the surfaces of antigen-presenting B-cells and monocytes, blocking the costimulatory signal between these cells and CD28 on T-cells that is the second message of T-cell receptor/MHC interaction. They are members of a group of proteins commonly termed biological response modifiers (BRMs) or biological disease-modifying antirheumatic drugs (bDMARDs). The major CD80/CD86 inhibitor, abatacept, is not classified as a slow-acting antirheumatic drug (SAARD), because it is considered to have more specific actions and because its therapeutic actions are produced rapidly. Belatacept is a fusion protein which is closely related to abatacept. It is used to prolong kidney grafts.
Chemical Structures and Properties
Abatacept is a fully humanized fusion protein produced from the extracellular portion of cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) linked to the Fc portion...
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bruce, S. P., & Boyce, E. G. (2007). Update on abatacept: A selective costimulation modulator for rheumatoid arthritis. Annals of Pharmacotherapy, 41(7), 1153–1162.
Cutolo, M., & Nadler, S. G. (2013). Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmunity Reviews, 12(7), 758–767.
Furie, R., Nicholls, K., Cheng, T. T., Houssiau, F., Burgos-Vargas, R., Chen, S. L., et al. (2014). Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. Arthritis & Rheumatology, 66(2), 379–389.
Genant, H. K., Peterfy, C. G., Westhovens, R., Becker, J. C., Aranda, R., Vratsanos, G., et al. (2008). Abatacept inhibits progression of structural damage in rheumatoid arthritis: Results from the long-term extension of the AIM trial. Annals of the Rheumatic Diseases, 67(8), 1084–1089.
Goëb, V., Buch, M. H., Vital, E. M., & Emery, P. (2009). Costimulation blockade in rheumatic diseases: Where we are? Current Opinion in Rheumatology, 21(3), 244–250.
Her, M., & Kavanaugh, A. (2013). Treatment of spondyloarthropathy: The potential for agents other than TNF inhibitors. Current Opinion in Rheumatology, 25(4), 455–459.
Iannone, F., & Lapadula, G. (2012). The inhibitor of costimulation of T cells: Abatacept. Journal of Rheumatology, 89(Suppl.), 100–102.
Nam, J. L., Ramiro, S., Gaujoux-Viala, C., Takase, K., Leon-Garcia, M., Emery, P., et al. (2014). Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73(3):516–528.
Rabaneda, E. F. V., Herrero-Beaumont, G., & Castaneda, S. (2013). Update on the use of abatacept for the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology, 9(7), 599–621.
Rostaing, L., Vincenti, F., Grinyo, J., Rice, K. M., Bresnahan, B., Steinberg, S., et al. (2013). Long-term belatacept exposure maintains efficacy and safety at 5 years: Results from the long-term extension of the BENEFIT study. American Journal of Transplantation, 13(11), 2875–2883.
Sandborn, W. J., Colombel, J. F., Sands, B. E., Rutgeerts, P., Targan, S. R., Panaccione, R., et al. (2012). Abatacept for Crohn’s disease and ulcerative colitis. Gastroenterology, 143(1), 62–69.
van Vollenhoven, R. F., Parodis, I., & Levitsky, A. (2013). Biologics in SLE: Towards new approaches. Best Practice & Research in Clinical Rheumatology, 27(3), 341–349.
Weinblatt, M., Schiff, M., Goldman, A., Kremer, J., Luggen, M., Li, T., et al. (2007). Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomised clinical trial. Annals of the Rheumatic Diseases, 66(2), 228–234.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this entry
Cite this entry
Pile, K.D., Graham, G.G., Mahler, S.M. (2016). CD80/86 Inhibitors: Abatacept. In: Parnham, M.J. (eds) Compendium of Inflammatory Diseases. Springer, Basel. https://doi.org/10.1007/978-3-7643-8550-7_20
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8550-7_20
Published:
Publisher Name: Springer, Basel
Print ISBN: 978-3-7643-8530-9
Online ISBN: 978-3-7643-8550-7
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences